Indian regulator issues warning to licence or be penalised
This article was originally published in Clinica
Executive Summary
India’s medical device regulator has warned manufacturers and importers of the 10 kinds of device that fell under mandatory licensing rules in October 2005 that they will face penalties if they do not get their products licensed. Surinder Singh, the Drug Controller General of India issued a notice on the Central Drugs Standard Control Organisation (CDSCO) website last month to encourage manufacturers and importers to obtain the requisite licences from the relevant state’s licensing authority, which is then approved by the central licence approving authority. To fail to do so is to act unlawfully and will be penalised, said Dr Singh. The 10 medical device groups are: cardiac stents; drug-eluting stents; catheters; intra-ocular lenses; IV cannulae; bone cements; heart valves; scalp vein set; orthopaedic implants; and internal prosthetic replacements. Licence application forms can be obtained at www.cdsco.nic.in or email: [email protected]
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.